White Paper

Model-Informed Strategies for ADC Development

Explore how model informed drug development can help ADC developers optimize dosing, reduce uncertainty, strengthen…

Danielle PillsburySeptember 22, 2026

Poster

PBPK Modelling of Bispecific Monoclonal Antibody Tumour Targeting Specificity

Explore how PBPK modelling evaluates the in vivo tumour-targeting specificity of bispecific monoclonal antibodies (bsmAbs),…

CertaraJune 25, 2026

Blog

ADC dose optimization: Applying model-informed strategies in development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

CertaraApril 22, 2026

On-Demand Webinar

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

Learn how model-informed strategies support ADC labeling, dose optimization, and market access through integrated evidence…

CertaraApril 10, 2026

On-Demand Webinar

Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs)

Watch this on-demand webinar to learn how model-informed strategies using PopPK, PBPK, and QSP can…

CertaraMarch 25, 2026

Video

ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

Learn how model-informed drug development (MIDD) and quantitative systems pharmacology (QSP) support antibody-drug conjugate (ADC)…

CertaraMarch 13, 2026

Blog

ADC first-in-human (FIH) dose selection: Designing FIH studies for success

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

CertaraMarch 3, 2026

On-Demand Webinar

Start right, finish strong: Antibody-drug conjugate (ADC) studies for success

Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…

CertaraFebruary 23, 2026

Publication

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…

CertaraMarch 20, 2025

Publication

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…

CertaraDecember 9, 2024

ADC

Model-Informed Strategies for ADC Development

PBPK Modelling of Bispecific Monoclonal Antibody Tumour Targeting Specificity

ADC dose optimization: Applying model-informed strategies in development

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs)

ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

ADC first-in-human (FIH) dose selection: Designing FIH studies for success

Start right, finish strong: Antibody-drug conjugate (ADC) studies for success

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

Newsletter sign up

Quick links

Solutions

Contact